| Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma RJ Motzer, K Penkov, J Haanen, B Rini, L Albiges, MT Campbell, ... New England Journal of Medicine 380 (12), 1103-1115, 2019 | 2263 | 2019 |
| First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer AT Shaw, TM Bauer, F de Marinis, E Felip, Y Goto, G Liu, J Mazieres, ... New England Journal of Medicine 383 (21), 2018-2029, 2020 | 784 | 2020 |
| Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial RJ Motzer, PB Robbins, T Powles, L Albiges, JB Haanen, J Larkin, XJ Mu, ... Nature medicine 26 (11), 1733-1741, 2020 | 347 | 2020 |
| Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study F Blackhall, K Jao, L Greillier, BC Cho, K Penkov, N Reguart, M Majem, ... Journal of Thoracic Oncology 16 (9), 1547-1558, 2021 | 151 | 2021 |
| Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial M Gogishvili, T Melkadze, T Makharadze, D Giorgadze, M Dvorkin, ... Nature medicine 28 (11), 2374-2380, 2022 | 137 | 2022 |
| Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer KN Chi, D Rathkopf, MR Smith, E Efstathiou, G Attard, D Olmos, JY Lee, ... Journal of Clinical Oncology 41 (18), 3339-3351, 2023 | 131 | 2023 |
| Biomarker analyses from JAVELIN Renal 101: Avelumab+ axitinib (A+ Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). TK Choueiri, L Albiges, JBAG Haanen, JMG Larkin, M Uemura, SK Pal, ... Journal of Clinical Oncology 37 (15_suppl), 101-101, 2019 | 94 | 2019 |
| Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN … BJ Solomon, TM Bauer, SH Ignatius Ou, G Liu, H Hayashi, A Bearz, ... Journal of Clinical Oncology 40 (31), 3593-3602, 2022 | 71 | 2022 |
| JAVELIN Renal 101: a randomized, phase 3 study of avelumab+ axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC) RJ Motzer, K Penkov, J Haanen, BI Rini, L Albiges Ann Oncol 29 (Suppl. 8), mdy424. 036, 2018 | 52 | 2018 |
| Veliparib in combination with carboplatin and etoposide in patients with treatment-naïve extensive-stage small cell lung cancer: a phase 2 randomized study LA Byers, D Bentsion, S Gans, K Penkov, CH Son, A Sibille, ... Clinical Cancer Research 27 (14), 3884-3895, 2021 | 49 | 2021 |
| LBA6_PR JAVELIN renal 101: A randomized, phase III study of avelumab+ axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC) RJ Motzer, K Penkov, J Haanen, BI Rini, L Albiges, MT Campbell, ... Annals of Oncology 29 (suppl_8), mdy424. 036, 2018 | 37 | 2018 |
| LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) M Gogishvili, T Melkadze, T Makharadze, D Giorgadze, M Dvorkin, ... Annals of Oncology 32, S1328, 2021 | 26 | 2021 |
| Рак молочной железы у мужчин ВФ Семиглазов, ВВ Семиглазов, ГА Дашян, РМ Палтуев, ... Фарматека, 40-45, 2010 | 24 | 2010 |
| Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial AO Siefker-Radtke, N Matsubara, SH Park, RA Huddart, EF Burgess, ... Annals of Oncology 35 (1), 107-117, 2024 | 23 | 2024 |
| PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with … NM Tannir, N Agarwal, SK Pal, DC Cho, M Formiga, J Guo, DJ George, ... Journal of Clinical Oncology 38 (6_suppl), TPS763-TPS763, 2020 | 23 | 2020 |
| Cemiplimab plus chemotherapy versus chemotherapy alone in advanced NSCLC: 2-year follow-up from the phase 3 EMPOWER-Lung 3 part 2 trial T Makharadze, M Gogishvili, T Melkadze, A Baramidze, D Giorgadze, ... Journal of Thoracic Oncology 18 (6), 755-768, 2023 | 22 | 2023 |
| Опухолевые маркеры при раке молочной железы ВФ Семиглазов, ВВ Семиглазов, Г Дашян, А Бессонов, Р Палтуев, ... Врач, 2-7, 2011 | 22 | 2011 |
| Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium … J Haanen, J Larkin, TK Choueiri, L Albiges, BI Rini, MB Atkins, ... ESMO open 8 (3), 101210, 2023 | 21 | 2023 |
| Efficacy of avelumab+ axitinib (A+ Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101. JBAG Haanen, J Larkin, TK Choueiri, L Albiges, BI Rini, MB Atkins, ... Journal of Clinical Oncology 39 (15_suppl), 4574-4574, 2021 | 20 | 2021 |
| Индивидуализация адъювантной терапии рака молочной железы ВФ Семиглазов, ВВ Семиглазов, РМ Палтуев, ГА Дашян, АГ Манихас, ... Фарматека, 8-13, 2011 | 20 | 2011 |
Toni ChoueiriDana-Farber Cancer Institute在 dfci.harvard.edu 的电子邮件经过验证
